Ursodeoxycholic acid and its emerging role in attenuation of tumor growth in gastrointestinal malignancies.

about

Bile acids for cachexia therapy : Reply to the letter by Shailendra Kapoor: Ursodeoxycholic acid and its emerging role in attenuation of tumor growth in gastrointestinal malignancies.

P2860

Q42350699-302C4D98-BE30-4F5C-B94B-55D6710C8545

P2860

Ursodeoxycholic acid and its emerging role in attenuation of tumor growth in gastrointestinal malignancies.

Item

http://www.wikidata.org/entity/Q42350734

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Ursodeoxycholic acid and its e ...... gastrointestinal malignancies.

@en

Ursodeoxycholic acid and its e ...... gastrointestinal malignancies.

@nl

type

Item

label

Ursodeoxycholic acid and its e ...... gastrointestinal malignancies.

@en

Ursodeoxycholic acid and its e ...... gastrointestinal malignancies.

@nl

prefLabel

Ursodeoxycholic acid and its e ...... gastrointestinal malignancies.

@en

Ursodeoxycholic acid and its e ...... gastrointestinal malignancies.

@nl

P1476

Ursodeoxycholic acid and its e ...... gastrointestinal malignancies.

@en

P2093

Shailendra Kapoor

http://www.w3.org/2001/XMLSchema#string

P2860

Gender modifies the effect of ursodeoxycholic acid in a randomized controlled trial in colorectal adenoma patients.

Pro-apoptotic role of the MEK/ERK pathway in ursodeoxycholic acid-induced apoptosis in SNU601 gastric cancer cells.

The chemopreventive agent ursodeoxycholic acid inhibits proliferation of colon carcinoma cells by suppressing c-Myc expression.

Celecoxib and tauro-ursodeoxycholic acid co-treatment inhibits cell growth in familial adenomatous polyposis derived LT97 colon adenoma cells.

Ursodeoxycholic acid-induced inhibition of DLC1 protein degradation leads to suppression of hepatocellular carcinoma cell growth.

Ursodeoxycholic acid treatment in a rat model of cancer cachexia.

Lipid raft-dependent death receptor 5 (DR5) expression and activation are critical for ursodeoxycholic acid-induced apoptosis in gastric cancer cells.

A new amino acid derivative of ursodeoxycholate, (N-L-Glutamyl)-UDCA (UDCA-Glu), to selectively release UDCA in the colon.

Ursodeoxycholic acid switches oxaliplatin-induced necrosis to apoptosis by inhibiting reactive oxygen species production and activating p53-caspase 8 pathway in HepG2 hepatocellular carcinoma.

Ursodeoxycholic acid suppresses Cox-2 expression in colon cancer: roles of Ras, p38, and CCAAT/enhancer-binding protein.

P2888

s13539-012-0091-5

P304

277-278

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13539-012-0091-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-11-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233411706

http://www.w3.org/2001/XMLSchema#string

P698

23150116

http://www.w3.org/2001/XMLSchema#string

P932

3505581

http://www.w3.org/2001/XMLSchema#string

Ursodeoxycholic acid and its emerging role in attenuation of tumor growth in gastrointestinal malignancies.

about

P2860

P2860

Ursodeoxycholic acid and its emerging role in attenuation of tumor growth in gastrointestinal malignancies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P698

P932